Aláez-Versón Carlos Raúl, Lantero Elena, Fernàndez-Busquets Xavier
BIOIBERICA, Polígon Industrial 'Mas Puigvert,' Ctra. N-II, km. 680.6, ES-08389 Palafolls, Spain.
Nanomalaria Group, Institute for Bioengineering of Catalonia (IBEC), The Barcelona Institute of Science and Technology, Baldiri Reixac 10-12, ES-08028 Barcelona, Spain.
Nanomedicine (Lond). 2017 Jul;12(14):1727-1744. doi: 10.2217/nnm-2017-0127. Epub 2017 Jun 21.
Heparin is one of the oldest drugs, which nevertheless remains in widespread clinical use as an inhibitor of blood coagulation. The history of its identification a century ago unfolded amid one of the most fascinating scientific controversies turning around the distribution of credit for its discovery. The composition, purification and structure-function relationship of this naturally occurring glycosaminoglycan regarding its classical role as anticoagulant will be dealt with before proceeding to discuss its therapeutic potential in, among other, inflammatory and infectious disease, cancer treatment, cystic fibrosis and Alzheimer's disease. The first bibliographic reference hit using the words 'nanomedicine' and 'heparin' is as recent as 2008. Since then, nanomedical applications of heparin have experienced an exponential growth that will be discussed in detail, with particular emphasis on its antimalarial activity. Some of the most intriguing potential applications of heparin nanomedicines will be exposed, such as those contemplating the delivery of drugs to the mosquito stages of malaria parasites.
肝素是最古老的药物之一，然而作为一种血液凝固抑制剂，它仍在临床中广泛使用。一个世纪前它的发现历程，是在一场围绕其发现功劳归属的最引人入胜的科学争论中展开的。在继续讨论其在炎症和传染病、癌症治疗、囊性纤维化和阿尔茨海默病等疾病中的治疗潜力之前，将先探讨这种天然存在的糖胺聚糖作为抗凝剂的组成、纯化及其结构 - 功能关系。首次使用“纳米医学”和“肝素”这两个词的文献参考可追溯到2008年。从那时起，肝素的纳米医学应用呈指数级增长，将对此进行详细讨论，尤其着重于其抗疟活性。还将介绍肝素纳米药物一些最引人关注的潜在应用，比如那些考虑将药物递送至疟原虫蚊子阶段的应用。
